Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Clinical Pharmacology and Therapeutics|August 8, 2006
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancerJian-Feng Lu, Steve M Eppler, Julie Wolf, et al.Pharmaceutical Research|July 15, 2006
Modeling and simulation of sexual activity daily diary data of patients with female sexual arousal disorder treated with sildenafil citrate (Viagra)Laurent Claret, Eugene H Cox, Lynn McFadyen, et al.Cancer Chemotherapy and Pharmacology|July 30, 2016
Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baselineLaurent Claret, Jenny Zheng, Francois Mercier, et al.Clinical Pharmacology and Therapeutics|May 22, 2023
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling FrameworkColby S Shemesh, Phyllis Chan, Mathilde Marchand, et al.CPT: Pharmacometrics & Systems Pharmacology|July 19, 2022
Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitisAnita Moein, Tong Lu, Siv Jönsson, et al.Cancer Chemotherapy and Pharmacology|September 15, 2015
Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumorsKelong Han, Jin Y Jin, Mathilde Marchand, et al.Clinical Pharmacology and Therapeutics|July 13, 2024
Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre- and on-Treatment Prognostic BiomarkersSébastien Benzekry, Mélanie Karlsen, Célestin Bigarré, et al.Journal for Immunotherapy of Cancer|November 23, 2019
Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancerColby S Shemesh, Pascal Chanu, Kris Jamsen, et al.Journal of Clinical Pharmacology|May 16, 2022
Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and SimulationStephanie N Liu, Mathilde Marchand, Xiaoyan Liu, et al.Clinical and Translational Science|August 25, 2021
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)Benjamin Wu, Nitzan Sternheim, Priya Agarwal, et al.Pageof 2